


PRODUCT: RKI-1313**ALTERNATE NAME:** 1-(3-Methoxybenzyl)-3-[4-(pyridin-4-yl)thiazol-2-yl]urea**CATALOG #:** B1092-5, 25**AMOUNT:** 5 mg, 25 mg**STRUCTURE:****MOLECULAR FORMULA:** C₁₇H₁₆N₄O₂S**MOLECULAR WEIGHT:** 340.4**CAS NUMBER:** 1342276-76-9**APPEARANCE:** Crystalline solid**SOLUBILITY:** DMSO**PURITY:** ≥98% by HPLC**STORAGE:** Store at -20°C. Protect from air and light.**DESCRIPTION:** RKI-1313 weak inhibitor for ROCK2-dependent signaling and has less effect on phosphorylation levels of ROCK substrates. RKI-1313 serves as a negative control for RKI-1447 (Cat. No. 2472) which is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer.**REFERENCES:** Patel R.A, *et.al.* (2012). Cancer Res. **72**, 5025-34.**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.**RELATED PRODUCTS:**

Fasudil Monohydrochloride (Cat. No. 1787-10, 50)

RKI-1447 (Cat. No.2472-5, 25)

RKI-1313 (Cat. No.B1092-5, 25)

ROCK Inhibitor (Rockout) (Cat. No. 2342-5, 25)

Thiazovivin (Cat. No. 1681-1, 5)

EZSolution™ Thiazovivin (Cat. No. 1736-1)

EZSolution™ Thiazovivin, Sterile-Filtered (Cat. No. 1993-1)

Y-27632 Dihydrochloride (Cat. No. 1596-1, 5, 50)

EZSolution™ Y-27632 (Cat. No. 1784-5)

EZSolution™ Y-27632, Sterile-Filtered (Cat. No. 1994-5)

USAGE: FOR RESEARCH CH USE ONLY! Not to be used in humans